ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Simple Search Results

Didn't find what you were looking for? Try the Advanced Search »

  • 1
  • 2
  • Next Page »
Search Again »
  • Abstract Number: 0010 • ACR Convergence 2024

    Precision Editing of Cyclophilin a to Engineer Cyclosporine- and Voclosporin- Resistant Human CAR-T Cells

    Holly Wobma1, Francesca Alvarez-Calderon2, Jiayi Dong2, Alexandre Albanese2, Kayleigh Omdahl2, Rene Bermea3, Gillian Selig4, Marlana Winschel2, Elisa Rojas Palato2, Katherine Michaelis1, Xianliang Rui2, Bruce Blazar5, Susan Prockop2, Victor Tkachev3, Ulrike Gerdemann2 and Leslie Kean2, 1Division of Immunology, Boston Children's Hospital, Boston, MA, 2Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, 3Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, 4Harvard College, Boston, MA, 5Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy, University of Minnesota, Minneapolis, MN

    Background/Purpose: With exponential demand for chimeric antigen receptor (CAR) therapies for autoimmune disease, allogeneic options will be essential. Advantages include use of healthy donor cells,…
  • Abstract Number: 1545 • ACR Convergence 2024

    Rates of Sustained Complete Renal Response with Long-term Use of Voclosporin in AURORA 2

    Ernie Yap1, Matt Truman2, Cynthia Auguste1, Vanessa Birardi3 and Greg Keenan1, 1Aurinia Pharmaceuticals Inc., Edmonton, Canada, 2Aurinia Pharmaceuticals, Victoria, BC, Canada, 3Aurinia Pharmaceuticals Inc., Rockville, MD

    Background/Purpose: Unlike in many other disease states, there is no accepted definition for clinical response in lupus nephritis (LN). The Phase 3 AURORA 1 study…
  • Abstract Number: 0601 • ACR Convergence 2023

    Selective Disposition of Voclosporin, Cyclosporine, and Tacrolimus in Renal Tissue

    Simon Zhou1, Krishani Kumari Rajanayake2, Miao He2, Bo Wen2, Ankhbayar Lkhagva2, Ernie Yap3, Duxin Sun2, Jennifer Cross1, Kory Engelke1 and Robert B. Huizinga4, 1Aurinia Pharmaceuticals Inc., Rockford, MD, 2University of Michigan, Ann Arbor, MI, 3Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada, 4Reformation Consulting Services, North Saanich, BC, Canada

    Background/Purpose: The calcineurin inhibitors (CNI) cyclosporine (CSA) and tacrolimus (TAC) were revolutionary when first introduced for solid organ transplant. Voclosporin (VCS), a novel CNI, is…
  • Abstract Number: 0782 • ACR Convergence 2023

    Comparison of Dual-immunosuppressive Therapy with a Voclosporin-based, Triple-immunosuppressive Regimen for Lupus Nephritis in the ALMS and AURORA 1 Studies

    Maria Dall'Era1, Ernie Yap2, Matt Truman2, Lucy Hodge2 and Neil Solomons3, 1University of California San Francisco, San Francisco, CA, 2Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada, 3Neil Solomons Consulting Inc., Victoria, BC, Canada

    Background/Purpose: Dual-immunosuppressive regimens consisting of high-dose glucocorticoids and higher doses ( >2 g/day) of mycophenolate mofetil (MMF) are still frequently used for the initial management…
  • Abstract Number: 1505 • ACR Convergence 2023

    Long-term Safety and Efficacy of Voclosporin in Black Patients with Lupus Nephritis: Results from the AURORA 1 and AURORA 2 Studies

    Gabriel Contreras1, Matt Baker2, Lucy Hodge2 and Ernie Yap2, 1University of Miami Health System, Miami, FL, 2Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada

    Background/Purpose: Black patients with lupus nephritis (LN) are reported to have more severe disease, are often refractory to treatment, and have worse long-term outcomes. Voclosporin…
  • Abstract Number: 2326 • ACR Convergence 2023

    Efficacy and Safety of Voclosporin in Patients with Proteinuria > 2 G/g

    Emily Littlejohn1, Salem Almaani2, Vanessa Birardi3, Ernie Yap4 and Christopher Collins5, 1Cleveland Clinic, Cleveland, OH, 2Ohio State University Medical Center, Columbus, OH, 3Aurinia Pharmaceuticals Inc, Edmonton, AB, Canada, 4Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada, 5Formerly Aurinia Pharmaceuticals Inc., Copenhagen, Denmark

    Background/Purpose: Proteinuria is the most common manifestation of lupus nephritis and is a mediator of progressive kidney damage. Early reductions in urine protein creatinine ratio…
  • Abstract Number: 2345 • ACR Convergence 2023

    Paired Kidney Biopsies from the AURORA 2 Study of Voclosporin in Active Lupus Nephritis

    Samir Parikh1, Salem Almaani2, Arnon Arazi3, Huijuan Song1, Pearlly Yan1, Estela Puchulu-Campanella1, Clint Abner4, Ernie Yap4, Krista Piper4, Robert B. Huizinga5 and Henry Leher4, 1Ohio State University, Columbus, OH, 2Ohio State University Medical Center, Columbus, OH, 3Broad Institute of MIT and Harvard, Melrose, MA, 4Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada, 5Reformation Consulting Services, North Saanich, BC, Canada

    Background/Purpose: Voclosporin is approved for the treatment of adults with active lupus nephritis. Addition of voclosporin to mycophenolate mofetil (MMF) and low-dose glucocorticoids in the…
  • Abstract Number: 0355 • ACR Convergence 2022

    Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study

    Amit Saxena1, Dawn Caster2, Salem Almaani3, Amber Rosales4 and Henry Leher5, 1NYU School of Medicine, New York, NY, 2University of Louisville, Louisville, KY, 3The Ohio State University Medical Center, Columbus, OH, 4Aurinia Pharmaceuticals Inc., Rockville, MD, 5Aurinia Pharmaceuticals Inc, Rockville, MD

    Background/Purpose: Persistent proteinuria increases the risk of comorbidities in lupus nephritis, and rapid reductions in protein have shown to be predictive of improved long-term renal…
  • Abstract Number: 0356 • ACR Convergence 2022

    Early Reductions in Proteinuria with Voclosporin Treatment Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials

    Anca Askanase1, Lucy Hodge2, Vanessa Birardi3 and Henry Leher3, 1Columbia University Medical Center, New York, NY, 2Aurinia Pharmaceuticals, Seattle, WA, 3Aurinia Pharmaceuticals Inc, Rockville, MD

    Background/Purpose: Voclosporin, a novel calcineurin inhibitor, is approved for the treatment of adults with lupus nephritis in combination with background immunotherapy and was successfully tested…
  • Abstract Number: 0357 • ACR Convergence 2022

    Voclosporin Is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations

    Hans-Joachim Anders1, Raymond Federico2, Vanessa Birardi3 and Henry Leher3, 1University of Munich, Munich, Germany, 2Aurinia Pharmaceuticals, Inc., Victoria, BC, Canada, 3Aurinia Pharmaceuticals Inc, Rockville, MD

    Background/Purpose: Pooled data from the Phase 2 AURA-LV and Phase 3 AURORA 1 studies demonstrated that adding voclosporin, a novel calcineurin inhibitor, to mycophenolate mofetil…
  • Abstract Number: 0358 • ACR Convergence 2022

    Long-term Safety and Efficacy of Voclosporin in Hispanic and Latino Patients with Lupus Nephritis

    Ellen M. Ginzler1, Amit Saxena2, Victoria Bal3, Vanessa Birardi4 and Henry Leher4, 1SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, 2NYU School of Medicine, New York, NY, 3Aurinia Pharmaceuticals, Inc., Victoria, BC, Canada, 4Aurinia Pharmaceuticals Inc, Rockville, MD

    Background/Purpose: The AURORA 1 study demonstrated that addition of voclosporin to MMF and low-dose steroids significantly increased complete renal response rates at 52 weeks, with…
  • Abstract Number: 1653 • ACR Convergence 2022

    Voclosporin for Lupus Nephritis: Assessment of Long-Term Safety and Efficacy Including Renal Outcome over Three Years of Treatment in the Phase 3 AURORA 1 and AURORA 2 Studies

    Cristina Arriens1, Samir Parikh2, Lucy Hodge3, Chris Mela4 and Henry Leher5, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2The Ohio State University, Columbus, OH, 3Aurinia Pharmaceuticals, Seattle, WA, 4Aurinia Pharmaceuticals, Inc., Victoria, BC, Canada, 5Aurinia Pharmaceuticals Inc, Rockville, MD

    Background/Purpose: In the Phase 3 AURORA 1 study, the addition of voclosporin to mycophenolate mofetil (MMF) and low-dose steroids led to significant reductions in proteinuria…
  • Abstract Number: 1425 • ACR Convergence 2021

    Voclosporin for Lupus Nephritis: Interim Analysis of the AURORA 2 Extension Study

    Amit Saxena1, Christopher Mela2 and Antonia Coeshall3, 1NYU School of Medicine, New York, NY, 2Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, 3Aurinia Pharmaceuticals Inc., Rockville

    Background/Purpose: Voclosporin, a novel calcineurin inhibitor (CNI), has been tested successfully in 2 pivotal trials in adult patients with lupus nephritis (LN). Previously reported results…
  • Abstract Number: 1751 • ACR Convergence 2021

    Voclosporin Is Effective in Achieving Complete Renal Response Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials

    Anca Askanase1, Simrat Randhawa2, Laura Lisk3 and Paola Mina-Osorio4, 1Columbia University Medical Center, New York, NY, 2Aurinia Pharmaceuticals Inc., Seattle, WA, 3Aurinia Pharmaceuticals Inc., Victoria, ON, Canada, 4Aurinia Pharmaceuticals Inc., New York, NY

    Background/Purpose: Voclosporin is a novel calcineurin inhibitor recently approved for the treatment of adult patients with active lupus nephritis in combination with background immunosuppressive therapy.…
  • Abstract Number: 1752 • ACR Convergence 2021

    Efficacy of Voclosporin in Recent Onset Lupus Nephritis

    Meggan Mackay1, Matt Truman2, Nicole England2, Vanessa Birardi3 and Paola Mina-Osorio4, 1Feinstein Institutes for Medical Research, Manhasset, NY, 2Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, 3Aurinia Pharmaceuticals Inc, Rockville, MD, 4Aurinia Pharmaceuticals Inc., New York, NY

    Background/Purpose: Voclosporin is a novel calcineurin inhibitor recently approved for the treatment of adults with active lupus nephritis (LN) in combination with background immunosuppressive therapy.…
  • 1
  • 2
  • Next Page »
Search Again »

Didn't find what you were looking for? Try the Advanced Search »

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology